Is tigecycline a common cure for certain diseases?

Is tigecycline a common cure for certain diseases?

Tigecycline is an antibiotic used in hospitals for serious infections when other treatments fail. It treats complicated skin infections, abdominal infections, and community-acquired pneumonia caused by resistant bacteria.

Do doctors use it as a first choice?

Doctors rarely prescribe tigecycline first. Guidelines recommend it mainly when standard antibiotics cannot cover resistant organisms like MRSA or multidrug-resistant Gram-negative bacteria.

What limits its wider use?

The drug carries an FDA boxed warning for higher death rates than other antibiotics in certain trials. Side effects include nausea, vomiting, and liver enzyme increases. These risks keep it reserved for difficult cases.

Can it treat other infections?

Tigecycline is not approved for bloodstream infections or urinary tract infections. Blood levels stay low, making it unsuitable for those sites.

How long does treatment last?

Standard courses run 5 to 14 days depending on the infection site and patient response. Shorter courses are preferred when clinical improvement occurs quickly.

When does the patent expire?

The main U.S. patent for tigecycline expired in 2015, allowing generic versions. Several manufacturers now produce it, lowering cost compared with the original brand.

Who makes generic tigecycline?

Pfizer markets the originator product Tygacil. Generic suppliers include Teva, Mylan, and Fresenius Kabi. Prices vary by hospital contracts and formulation.

Are biosimilars available?

Tigecycline is a small-molecule drug, so biosimilars do not apply. Generic chemical copies have entered most markets.

What do patients report about side effects?

Nausea occurs in up to 30 percent of patients. Some also note dizziness or skin reactions. Doctors monitor liver tests during longer courses.

Can resistance develop during treatment?

Resistance to tigecycline can emerge, especially in Enterobacteriaceae and Acinetobacter. Hospitals track local susceptibility patterns before starting therapy.

[1] https://www.drugpatentwatch.com/drug/tigecycline